Home › Takeda Licenses Rights To Use ImmunoGen, Inc.'s Novel Antibody-Drug Conjugate Technology
 

Keywords :   


Takeda Licenses Rights To Use ImmunoGen, Inc.'s Novel Antibody-Drug Conjugate Technology

2015-04-01 08:41:48| drugdiscoveryonline Home Page

Takeda Pharmaceutical Company Limited and ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its state-of-the-art antibody-drug conjugate (ADC) technology, recently announced that Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology – including ImmunoGen’s new DNA-acting IGN payload agents – to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets

Tags: rights technology licenses conjugate

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07High input costs, rising interest rates continue to weigh on farmer sentiment
03.07EPAs PFAS Hazardous Substance Rule on the Horizon
03.07Sensory analysis shows pork has 111 unique flavor nuances
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Public Advisory Number 19A
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07This Month in Waste: Top Stories for June 2024
03.07'Floodgates open' for legal action against water firms
More »